SEQUOIA
May 6, 2026
Zanubrutinib as an effective 1st line treatment for CLL, irrespective of del(17p) status
Where evidence meets expertise
STudy in the Picture (STiP) brings clinical research into sharp focus through concise, expert-driven summaries. Each STiP distils a single clinical study into its essential elements, from rationale and design to key results and clinical relevance, without compromising scientific depth.
Two formats, one mission
STiP │ Congress Highlights
Tied to the most important oncology congresses, these STiPs go beyond the headline results. Developed alongside expert video interviews recorded on-site, each piece unpacks study rationale, design, and key findings, and connects you to the full discussion via the congress video page.
SEQUOIA & ALPINE
May 6, 2026
Zanubrutinib in the treatment of chronic lymphocytic leukemia Six-year results from
SEQUOIA & ALPINE with Long Term Extension
STiP │ Key Publications
Not every breakthrough happens at a congress. These STiPs focus on landmark journal publications, giving pivotal studies the depth they deserve. Where available, an expert video interview adds further insight and clinical perspective.